CRSP · CRISPR Therapeutics AG
CRISPR Therapeutics AG develops CRISPR/Cas9-based gene-editing therapies aimed at treating serious diseases. The stock moved sharply on 2026-04-13 amid heightened volume and attention in multiomics research coverage.
Recent proof-backed thesis calls
No open analyst calls. Two recent research items reference CRSP: an ARK Big Ideas 2026 segment on Multiomics and a shortlist entry for a YouTube interview from the 2026 Abundance360 Summit.
A social post claims California is about to pass a bill banning “aesthetic” gene editing in pets and that the bill cites the author’s company; it frames this as regulation of technology (methods) rather than outcomes. No bill number, timing, or details are provided, so tradability is limited without verification.
The source is a one-line conceptual statement about aging as a drift from optimal gene expression. It provides no company, product, catalyst, timing, or investable details, so it is not directly actionable for trading without additional context (e.g., specific targets, modalities, clinical readouts, or firms).
The provided excerpt is only the cover/table-of-contents portion of CRISPR Therapeutics’ Form 10-Q for quarter ended 2026-03-31. It confirms filing status, exchange listing (Nasdaq: CRSP), and basic corporate identifiers, but contains no financial results, guidance, pipeline updates, cash runway, risk-factor changes, or other value-moving disclosures. As-is, it is not tradable/actionable.
Short listing for a YouTube interview filmed at the 2026 Abundance360 Summit with Ben Lamm (Colossal) titled “AI + Synthetic Biology: The Most Transformative Technology in Human History.” The listing notes the video but the transcript could not be retrieved. Content likely promotes Colossal’s synthetic biology/de‑extinction work and argues AI+synthbio is transformational. No new corporate filings, financing, or measurable operational updates are present in the item.
ARK’s Big Ideas 2026 (Multiomics) segment outlines the investment case for “multiomics” (integrating genomics, transcriptomics, proteomics, etc.) as biology moves from single-layer measurement to multi-layer data + computation. The talk highlights downstream implications across (1) data generation (sequencing/single-cell/proteomics platforms), (2) diagnostics (earlier, cheaper, more precise testing), (3) drug development (better target ID/stratification), and (4) therapeutics (more precise, pote
This excerpt is only the cover page/header of CRISPR Therapeutics’ FY2025 Form 10‑K (fiscal year ended 2025‑12‑31). It contains listing/filing status information but no financial results, guidance, risk updates, pipeline progress, or MD&A detail—so it provides minimal tradable signal by itself.
This excerpt is only the cover/boilerplate of CRISPR Therapeutics’ 10‑Q for the quarter ended 2025‑09‑30 and does not include financial results, cash runway, pipeline updates, guidance, or risk-factor changes. As provided, it offers minimal tradable, incremental information beyond confirming continued SEC reporting/listing compliance.
Provided excerpt is only the cover/header portion of CRISPR Therapeutics AG’s Form 10-Q for the quarter ended 2025-06-30 (listing symbol/exchange and SEC filing compliance checkboxes). It contains no financial statements, guidance, program updates, or risk-factor changes, so it is minimally actionable for trading beyond confirming continued reporting/listing compliance.
Latest market-close explanation
On 2026-04-13 CRSP rose 7.05% to close at $54.83 (prior close $51.22), trading between $51.05 and $55.09 with volume +110.9% vs. the prior session. Recent internal coverage included Big Ideas 2026: Multiomics.
What most likely happened - CRSP closed down 2.1% to $46.54 on lighter-than-normal volume (volume -22.7%), with the stock opening at the high ($48.07) and sliding intraday to $45.92. No company or sector headlines or earnings were identified, so the move looks like muted profit‑taking/position adjustment rather than a news-driven repricing. The low volume suggests limited conviction behind the selloff. What to watch next - Catalyst calendar: monitor any near‑term clinical readouts, regulatory updates, or partner (notably Vertex) announcements that could drive conviction moves. - Sector flow: watch biotech/CRISPR peers (IV/BEAM etc.) and biotech ETFs for correlated strength/weakness that could lift or pressure CRSP. - Price/volume signals: a recovery above the open/resistance near $48 on rising volume would signal renewed buying; sustained drops below ~$45.50–46 on higher volume would indicate a deeper pullback. - Corporate filings and insider activity: new financing, collaborations, or material 8‑K/SEC filings could change the picture quickly. Bottom line: today’s dip looks like low‑conviction profit taking; traders should wait for a volume-backed move or a specific catalyst before treating it as a trend change.
Current stance
No active internal recommendation is posted. Market movement and increased volume on 2026-04-13 merit attention, while research mentions point to thematic interest in multiomics and synthetic biology.
- sell via CRSP 10-Q report for 2026-03-31 from https://www.sec.gov/edgar/search/ (confidence 0.60)
- beneficiary via High-beta genetic medicine sentiment basket (theme-driven, not company-specific) from https://x.com/prof_horvath (confidence 0.33)
- risk via Regulatory headline risk for gene-editing platforms (low-conviction, needs verification) from https://x.com/webuildlife (confidence 0.22)
Top authors on this asset
Active and historical ticker theses
No active plays at this time.
No actionable trading catalyst can be extracted from the provided 10‑K header alone.
CRSP 10-Q report for 2026-03-31
High-beta genetic medicine sentiment basket (theme-driven, not company-specific)
Regulatory headline risk for gene-editing platforms (low-conviction, needs verification)
CRSP 10-Q report for 2025-09-30
Longevity/aging-as-gene-expression-drift is a long-horizon narrative tailwind for gene-expression measurement and modulation platforms.
Unlock full asset monitoring
Monitor follow-up filings and company updates for confirmation of operational or clinical catalysts; consider volume and thematic research when evaluating conviction.